secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0001104659-24-090559
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode receives two Nasdaq deficiency notices; faces potential delisting
---------------------------------------------------------------------------

- On Aug 13, 2024, Nasdaq notified TransCode of minimum bid price deficiency; stock closed below $1.00 for 30 consecutive days.
- On Aug 15, 2024, Nasdaq notified of stockholders' equity deficiency; reported equity $1.32M vs $2.5M minimum.
- Company is ineligible for 180-day compliance period due to two reverse stock splits in prior 2 years with cumulative ratio >250:1.
- Company intends to request a hearing before Nasdaq Hearings Panel to stay any suspension/delisting action.
- Pro forma equity with $2.4M July 2024 offering is ~$3.7M, but Staff acceptance is uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924090559/0001104659-24-090559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924090559/tm2421945d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-090559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer